Levy Raphi sold $248K of DRTS
Levy Raphi (Chief Financial Officer) sold 17,730 shares of Alpha Tau Medical Ltd. (DRTS) at $14.00 ($0.25M total) on 2026-08-11 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure updates the record of insider activity and may influence short-term sentiment, but it does not introduce new company fundamentals.
Market read
Traders may note the insider sale, but the 10b5-1 structure and lack of fundamental news suggest limited trading edge.
What to watch
The article does not disclose motivations, other insider transactions, or whether there were concurrent buys; without that context, signal quality is low.
Background
The article is a primary-source SEC Form 4 insider transaction disclosure for Alpha Tau Medical Ltd.
Ticker impact
Alpha Tau Medical CFO Levy Raphi sold 17,730 shares at $14.0032 on 2026-08-11 under a pre-arranged 10b5-1 plan, per Form 4.
Likely limited near-term price impact; any reaction should be muted given the pre-arranged 10b5-1 plan.
The filing provides transaction size, price, and post-sale holdings, but no new guidance, contract, trial, or regulatory development. 10b5-1 plans are typically treated as less informative about near-term fundamentals.
Market effects
No clear sector read-through from a single 10b5-1 insider sale.
None indicated.
None indicated.
Counterpoint
The sale could be routine liquidity management under a pre-arranged plan, so any bearish interpretation may be overdone.
Key entities
- issuerAlpha Tau Medical Ltd.
Company whose CFO insider sale is disclosed on SEC Form 4.
- insiderLevy Raphi
Chief Financial Officer who sold shares under a pre-arranged 10b5-1 plan.
